WHITEPAPER:

Reducing Risk in Government Pricing and Programs Compliance

" Manufacturers have been hit with fines totaling $8B in recent years "

With sweeping health care reform legislation now in place, it is once again time for pharmaceutical and biotech manufacturers to comb through the dense legalise and figure out what processes and systems they need to re-configure to stay in compliance. Although the majority of the Affordable Care Act focuses on insurance reform and expanded coverage, there are still several significant changes that affect pharma and biotech, including Medicaid rebate increases, 340B expansion, and changes to Medicare Part D.

This report reviews the risk environment for pharmacuetical manufacturers with government business and offers tip for evaluating solutions and best practices to reduce regulatory exposure.

Please fill the form below to download the whitepaper.

Lead Source:

Sub Industry:

utm_last_campaign:

utm_last_content:

utm_last_medium:

utm_last_source:

utm_last_term:

Demandbase SID:

Dbase-Company Name:

Dbase-Industry:

Dbase-Sub Industry:

Dbase-Employee Range:

Dbase-Revenue Range:

Dbase-Street Address:

Dbase-City:

Dbase-State:

Dbase-Zip:

Dbase-Phone:

Dbase-Country Name:

Dbase-Primary SIC:

Watch List Account Type:

Watch List Account Status:

Watch List Campaign Code:

Watch List Account Owner:

Dbase-Data Source:

WHITEPAPER:

Reducing Risk in Government Pricing and Programs Compliance

Please fill the form below to download the whitepaper.

Pharmaceutical Customers